NCT04310631

Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 5 (actual)
• Sponsor: Federico II University · Academic / Other
• Sex: Male
• Age: 19 Years – 30 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Detailed description

Coats disease is an idiopathic retinal vascular disorder, occurs in young males, and is characterized by retinal telangiactasias, numerous yellowish exudates in the subretinal space, macular edema, hemorrhages and, in advanced end-stage, by exudative retinal detachment. Ranibizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Ranibizumab in Coats disease.

Conditions

• Coats Disease

Interventions

Type	Name	Description
DRUG	Ranibizumab Injection	Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections

Timeline

• Start date: 2016-01-01
• Primary completion: 2019-12-31
• Completion: 2019-12-31
• First posted: 2020-03-17
• Last updated: 2020-03-17

Locations

1 site across 1 country: Italy